Terns Pharmaceuticals’ TERN-701 Receives the US FDA’s Orphan Drug Designation to Treat Chronic Myeloid Leukemia
Shots:
- The US FDA has granted orphan drug designation to the company’s TERN-701, allosteric BCR-ABL tyrosine kinase inhibitor, for treating chronic myeloid leukemia (CML)
- The P-I (CARDINAL) dose escalation & expansion study will investigate the safety, efficacy, tolerability & PK of TERN-701 for the treatment of chronic myeloid leukemia. The data from initial dose escalation arms is anticipated in H2’24
- Additionally, Hansoh Pharmaceutical (HS-10382) has the development rights of TERN-701 in the greater China region while Terns holds global (excl. greater China) rights to develop & commercialize the drug along with access to data generated by Hansoh
Ref: Terns Pharmaceuticals | Image: Terns Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
